Efficacy and safety of rivaroxaban compared with vitamin K antagonists for peri-procedural anticoagulation in catheter ablation of atrial fibrillation: a systematic review and meta-analysis

Mate Vamos¹, Riccardo Cappato², Francis E. Marchlinski³, Andrea Natale⁴, and Stefan H. Hohnloser¹*

¹Department of Cardiology, Division of Clinical Electrophysiology, J.W. Goethe University, Theodor-Stern-Kai 7, Frankfurt am Main D 60590, Germany; ²Arrhythmia and Electrophysiology Center, IRCCS Humanitas, Rozzano, Milan, and Cliniche Gavazzeni, Bergamo, Italy; ³Section of Cardiac Electrophysiology, Hospital of the University of Pennsylvania, Philadelphia, PA, USA; and ⁴Texas Cardiac Arrhythmia Institute at St. David’s Medical Center, Austin, TX, USA

Received 26 August 2015; accepted after revision 10 November 2015; online publish-ahead-of-print 20 January 2016

Rivaroxaban is increasingly used in patients undergoing catheter ablation of atrial fibrillation (AF). In the absence of large controlled trials, a comprehensive meta-analysis of the literature appears to be the best way to obtain reliable evidence on rare peri-procedural outcomes such as thromboembolic or bleeding events. We aimed to provide a detailed analysis of currently available data on safety and efficacy of peri-procedural rivaroxaban in patients undergoing AF ablation. We performed a systematic search of the English language literature for studies comparing peri-procedural rivaroxaban therapy with vitamin K antagonists (VKAs) and reporting detailed data on bleeding and/or thromboembolic complications. The Peto odds ratio (POR) was used to pool data into a fixed-effect meta-analysis. A total of 7400 patients undergoing catheter ablation were included in 15 observational and 1 randomized studies of which 1994 were receiving rivaroxaban and 5406 VKA. The risk of thromboembolism trended to be lower in the rivaroxaban group [4/1954 vs. 19/5219, POR 0.40, 95% confidence interval (CI), 0.16–1.01, P = 0.052]. Major bleeding events occurred in 23 of 1994 cases (1.15%) in the rivaroxaban and 90 of 5406 (1.66%) in the VKA group (POR 0.74, 95% CI, 0.46–1.21, P = 0.23). A total of 87 minor bleeding events were reported in 1753 patients (4.96%) in the rivaroxaban group and in 165 of 4009 patients (4.12%) in the VKA group (POR 0.84, 95% CI 0.63-1.11, p = 0.22). In patients undergoing AF ablation, rivaroxaban appears to be an effective and safe alternative to VKA.

Keywords Rivaroxaban • Catheter ablation • Atrial fibrillation • Peri-procedural anticoagulation • Stroke • Oral anticoagulation

Introduction

Catheter ablation has evolved as the standard of care in selected patients with symptomatic atrial fibrillation (AF). Catheter ablation carries a notable risk for peri-procedural thromboembolic and bleeding events. A worldwide survey on peri-procedural complications revealed that 4.5% of patients experienced a major complication (major bleeding 2.8%, thromboembolic event 0.94%). According to the results of observational and randomized trials, uninterrupted warfarin therapy seems to be superior over bridging with unfractionated (UFH) or low-molecular-weight heparin (LMWH). However, vitamin K antagonist (VKA) therapy has known limitations such as a narrow therapeutic window, need for frequent dose adjustments based on repeated INR measurements, a long onset and offset time, many drug–drug interactions, to name the most important ones.

Novel oral anticoagulants (NOACs) have handling advantages over VKAs, including a fast onset of action, lack of requirement for routine coagulation monitoring, and fewer drug–drug interactions, thus simplifying anticoagulation management substantially.

* Corresponding author: Tel: +49 69 6301 7404; fax: +49 69 6301 7017. E-mail address: hohnloser@em.uni-frankfurt.de

© The Author 2016. Published by Oxford University Press on behalf of the European Society of Cardiology. This is an Open Access article distributed under the terms of the Creative Commons Attribution Non-Commercial License (http://creativecommons.org/licenses/by-nc/4.0/), which permits non-commercial re-use, distribution, and reproduction in any medium, provided the original work is properly cited. For commercial re-use, please contact journals.permissions@oup.com
Catheter ablation of atrial fibrillation (AF) is an established treatment modality but carries a distinct risk of thromboembolism. Hence, anticoagulation before, during, and after the procedure is mandatory. This systematic review and comprehensive meta-analysis of the current literature indicates that rivaroxaban appears to be an effective and safe alternative to vitamin K antagonists in patients undergoing catheter ablation of AF. It may offer advantages in terms of handling anticoagulation in this clinical scenario.

Moreover, large-scale randomized trials in the general AF population demonstrated non-inferior efficacy and safety of NOACs over warfarin.

In the setting of catheter ablation of AF, some small observational studies and one randomized trial indicated a similar safety and efficacy profile of rivaroxaban compared with warfarin. However, most of these studies comprised only small patient samples and were hence statistically underpowered for rare outcomes, i.e., thromboembolism or major bleeding. Accordingly, the present meta-analysis of all respective studies aims to provide comprehensive data on rivaroxaban in the setting of AF ablation.

Methods

Study selection

This systematic review was performed according to the PRISMA Statement for reporting systematic reviews and meta-analyses. Our predefined review protocol was published in the PROSPERO database under the registration number CRD42015017085.

A comprehensive search was conducted in MEDLINE, COCHRANE Library, and ‘Web’ databases from January 2010 through April 2015 focusing on full-sized papers published in the English language reporting data on the safety and efficacy of peri-procedural rivaroxaban in patients undergoing AF ablation. Abstracts were included when critically relevant. Studies eligible for inclusion were identified by using the following terms with all variations in spelling: ‘catheter ablation’, ‘rivaroxaban’, and ‘mouth/oral anticoagulants’. Additional publications were identified using the reference lists of selected manuscripts. Three reviewers independently evaluated all potentially relevant articles for eligibility.

The eligibility criteria for this meta-analysis were as follows:

1. Inclusion of patients undergoing catheter ablation of AF.
2. Reported peri-procedural bleeding and/or thromboembolic complications related to the use of interrupted or uninterrupted rivaroxaban therapy.
3. Investigated outcomes with an interrupted or uninterrupted VKA comparator arm.

Any disagreement was subsequently resolved by consensus. Studies reporting only composite patients groups, but no specific data on catheter ablation or investigated outcomes without a VKA comparator arm were excluded.

Baseline characteristics, study design, percentage of paroxysmal AF, details on peri-procedural anticoagulation (i.e., timing of the first-held and restarting dose of anticoagulants, possibly LMWH/heparin bridging), efficacy and safety outcomes were extracted from included studies independently by two investigators. Corresponding authors were contacted for unpublished information and permission in case of missing relevant data sets.

Endpoints of interest

The efficacy outcome was defined as a composite endpoint of symptomatic thromboembolic events including ischaemic stroke, transient ischaemic attack (TIA), or systemic thromboembolism. Major bleeding constituted the primary safety outcome. The definition of bleeding was mainly based on the criteria of the International Society of Thrombosis and Hemostasis. In general, major bleeding was defined as fatal bleeding, bleeding that was symptomatic and occurred in a critical area or organ, bleeding causing a drop in haemoglobin level of 2 g/dL or more, severe enough to require ≥2 units of blood, or a specific therapeutic intervention, or cessation of anticoagulation for >7 days. Pericardial effusions were considered as major bleeding events if it not specified otherwise. Minor bleeding consisted of any clinically noted bleeding not meeting criteria for major haemorrhage.

Statistical analysis

Methodological quality of all studies was assessed using the Methodological Index for Non-Randomized Studies (MINORS). The Peto odds ratio (POR) with 95% confidence intervals (CIs) was used to pool data into a fixed-effect meta-analysis given the low event rates for the overall effect in this meta-analysis. A Forest plot was constructed of individual trials with the pooled estimates. Heterogeneity between individual trial estimates was assessed using the Q statistic and I² statistic. For I², a value of >50% was considered to indicate significant heterogeneity. Publication bias was assessed using the funnel plot, the trim and fill method of Duval and Tweedie, and an adjusted rank correlation test according to Begg and Mazumdar. Sensitivity analyses regarding uninterrupted VKA or rivaroxaban therapy, use of LMWH/heparin bridging, and holding ≤2 dose or holding >2 doses of rivaroxaban were performed. All statistical analyses were conducted utilizing Comprehensive Meta-Analysis 3.3 (Biostat, Inc., USA).

Results

Study characteristics

As shown in Figure 1, a total of 16 studies were selected for the present analysis. These studies fulfilling our predefined selection criteria involved 7400 patients of which 1994 subjects received rivaroxaban. Of all identified studies, only one was a randomized controlled clinical trial, whereas the remainders were observational retrospective or prospective studies. The vast majority were single-centre observational studies, with the exception of three multicentre studies and one based on a national registry. Seven included reports were assessed to be high-quality publications (average MINORS score 16.2 ± 3.3). Table 1 provides details of all included studies.

The majority of the studies used rivaroxaban 15 or 20 mg OD. Two reports from Japan used 10 or 15 mg rivaroxaban OD. Ten studies used an uninterrupted VKA strategy. Most of the studies discontinued rivaroxaban 24–48 h prior to the procedure (i.e., typically held 1 or 2 doses) with or without LMWH/heparin bridging (Table 1). Rivaroxaban was generally resumed within 12 h after the procedure. Only 6 studies out of 15 assessed the efficacy and safety of an uninterrupted rivaroxaban regimen. The target activated clotting time (ACT) during ablation was between 300 and 400 s in most studies.
Efficacy and safety outcome events

A total of 23 thromboembolic events were observed in 15 studies. One study did not report data on efficacy.\(^{28}\) Fewer thromboembolic events were reported in rivaroxaban-treated patients compared with those receiving VKA (4/1954 vs. 19/5219; POR 0.40, 95% CI 0.16–1.01, \(P = 0.052; I^2 = 0\%\)) (Figure 2).

Major bleeding events were reported for all of the studies and were observed in 1.15% of rivaroxaban (23/1994) and 1.66% of VKA patients (90/5406) (POR 0.74, 95% CI 0.46–1.21, \(P = 0.23; I^2 = 0\%\)) (Figure 3). The overall rate of severe pericardial effusion/tamponade was 0.88% (65/7400).

Data for minor bleeding were available in 14 of 16 studies. Minor bleeding events were reported at a pooled rate of 4.96% (87/1753) in rivaroxaban-treated patients compared with 4.12% in VKA-treated patients (165/4009) (POR 0.84, 95% CI 0.63–1.11, \(P = 0.22; I^2 = 0\%\)) (Figure 4).

Only two fatal complications (one ruptured cerebral aneurysm on rivaroxaban and one vascular death on VKA) were reported.\(^{21,27}\) A consistent value of 0% of the \(I^2\) along all three outcome measures indicated lack of relevant statistical heterogeneity. The sensitivity analyses described in the method section revealed no significant differences compared with the main results (Supplementary material online, Table S1–3). There was a trend towards better performance of uninterrupted rivaroxaban as compared with interrupted (\(\geq 2\) doses held) for both, major and minor bleeding events (Figure 5).

Discussion

Main findings

The present meta-analysis of 15 observational studies\(^{12–26}\) and 1 recently published randomized trial\(^ {27}\) comprising 7400 patients undergoing AF ablation demonstrates similar efficacy and safety of rivaroxaban when compared with VKA in preventing thromboembolic and bleeding events during AF ablation.

Thromboembolic events during atrial fibrillation ablation

Catheter ablation has matured as an established treatment modality in patients with symptomatic AF. This procedure carries the risk of local and systemic complications, with stroke occurring at an incidence of 0.5–1.0%.\(^ {3}\) Atrial fibrillation ablation also carries a risk for silent cerebrovascular events, the consequences of which remain unclear.\(^ {37,38}\) The increased thromboembolic risk during AF ablation seems to be related to the underlying prothrombotic state associated with the arrhythmia and to specific ablation-related factors, such as placement of multiple venous sheaths, trans-septal punctures, activation of the clotting cascade via application of radiofrequency energy, and atrial stunning.\(^ {39}\)

Hence, there is a clear need to protect patients from thromboembolic events during AF ablation, but there is still no consensus regarding the optimal anticoagulation regimen. Current guidelines therefore recommend the use of uninterrupted warfarin,\(^ {1,2,40}\) mainly based on results of a randomized clinical trial demonstrating
| Study       | Design                               | Subjects total | Subjects rivaroxaban | Follow-up | Paroxysmal AF (%) | VKA type and dosing                          | Rivaroxaban dosing                                      | Quality (MINORS score) |
|------------|--------------------------------------|----------------|----------------------|-----------|-------------------|---------------------------------------------|--------------------------------------------------------|------------------------|
| Bernard    | Single-centre study                  | 119            | 75                   | 30 days   | R 57, VKA 50      | Warfarin, discontinued within 24 h prior to the procedure and restarted within 24 h after the procedure | Discontinued within 24 h prior to the procedure and restarted within 24 h after the procedure | 15                     |
| Gadiyaram  | Single-centre study                  | 338            | 54                   | n.a.      | n.a.              | Warfarin uninterrupted/ interrupted with LMWH bridging | Discontinued within 48 h prior to the procedure with LMWH bridging and restarted within 24 h after the procedure | 13                     |
| Lakkireddy | Multicentre, prospective, observational study | 642           | 321                  | 30 days   | R 51, VKA 51      | Warfarin, uninterrupted                       | Uninterrupted                                           | 20                     |
| Providencia| Single-centre, prospective, observational study | 380           | 188                  | 30 days   | R 63, VKA 53      | Fludione/warfarin/ acenocoumarol, interrupted with heparin/LMWH bridging | Discontinued within 24–48 h prior to the procedure | 20.5                   |
| Stepanyan  | Retrospective analysis               | 212            | 98                   | ≥ 30 days  | 71                | Warfarin, uninterrupted                       | Discontinued within 36 h prior to the procedure with heparin bridging | 17.5                   |
| Murakawa   | National registry                    | 1845           | 37                   | n.a.      | 64                | Warfarin, interrupted                         | Typically discontinued >24 h prior to the procedure | 12                     |
| Mendoza    | Single-centre study                  | 138            | 80                   | 30 days   | R 67, VKA 43      | Warfarin, uninterrupted                       | Uninterrupted                                           | 15                     |
| Tao        | Single-centre study                  | 140            | 70                   | n.a.      | 72.9              | Warfarin, uninterrupted                       | Uninterrupted                                           | 14                     |
| Toyama     | Single-centre study                  | 281            | 50                   | n.a.      | n.a.              | Warfarin, interrupted                         | Discontinued within 24 h prior to the procedure and restarted at 2 h after the procedure | 13                     |
| Winkle     | Single-centre retrospective study     | 1300           | 187 (pre-ablation)   | n.a.      | R 27, VKA 22      | Warfarin, interrupted                         | Discontinued within 36 h prior to the procedure without LMWH bridging and restarted within 24 h after the procedure | 14.5                   |
| Kochhauser | Single-centre retrospective study     | 460            | 141                  | 11–18 months | 69–75            | Warfarin, interrupted with LMWH bridging      | Last dose in the morning of the day before the procedure and resumed 8 h post-sheath removal | 17                     |
| Di Biase   | Multicentre study                    | 392            | 196                  | n.a.      | 0                 | Warfarin, uninterrupted                       | Uninterrupted                                           | 15                     |
| Dillier    | Single-centre non-randomized study   | 544            | 272                  | n.a.      | R 49, VKA 46      | Phenprocoumon, uninterrupted                 | Uninterrupted                                           | 18.5                   |
| Snipelisky | Single-centre retrospective study     | 127            | 40                   | n.a.      | n.a.              | Warfarin, uninterrupted                       | Discontinued within 12 h prior to the procedure         | 13.5                   |
| Ambruster  | Retrospective cohort study           | 234            | 61                   | n.a.      | n.a.              | Warfarin, uninterrupted                       | By most patients discontinued >24 h and restarted within 12 h after the procedure | 17                     |
| Cappato    | Multicentre randomized controlled trial | 248           | 124                  | 30 ± 5 days | 73.4              | Warfarin, uninterrupted                       | Uninterrupted                                           | 24                     |
superior efficacy and safety of uninterrupted VKA therapy vs. bridging.\(^5\)

However, limitations of and difficulties in using VKA therapy are well known.\(^6\)–\(^8\) Given the non-inferior efficacy and safety of NOACs in general stroke prevention in AF,\(^9\)–\(^11\) it seems logical to evaluate these new compounds also in the setting of AF ablation. The first observational studies in patients undergoing AF ablation used dabigatran. A meta-analysis of 10 such studies comprising 3648 patients showed similar efficacy of this compound compared with warfarin when given during AF ablation.\(^41\)

For rivaroxaban, several observational studies reported similar findings.\(^12\)–\(^26\) In addition, the first prospective randomized study of a NOAC in 228 ablation patients randomized to rivaroxaban or VKA was recently published.\(^27\) The present comprehensive meta-analysis of all rivaroxaban studies in the setting of AF ablation confirms the efficacy of this NOAC in preventing cerebrovascular events during AF ablation. Only 23 strokes/TIA were reported in almost 7400 patients (overall incidence 0.32%). This overall event rate was lower than previously reported,\(^3\) perhaps due to increasing experience of centres performing AF ablations, improved ablation...
techniques, or due to underreporting in these mostly observational studies. Despite the small numbers, there was a trend towards less cerebrovascular events with rivaroxaban than with VKA. Our study extends the findings of previous meta-analyses\textsuperscript{42–45} by including data from 7400 patients from 15 retrospective and 1 prospective randomized studies.

### Table 1: Risk of bleeding during atrial fibrillation ablation

| Study name       | Events / total | Rivaroxaban (Peto odds ratio) | VKA (Peto odds ratio) | Lower limit | Upper limit | p-Value |
|------------------|----------------|-----------------------------|-----------------------|-------------|-------------|---------|
| Bernard, 2013    | 1 / 75         | 0.27                        | 0.03                  | 2.91        | 0.28        |
| Lakireddy, 2013  | 16 / 321       | 0.83                        | 0.42                  | 1.65        | 0.60        |
| Providencia, 2014| 3 / 188        | 0.76                        | 0.17                  | 3.40        | 0.72        |
| Stepanyan, 2014  | 3 / 98         | 1.76                        | 0.30                  | 10.38       | 0.53        |
| Murakawa, 2014   | 1 / 37         | 1.70                        | 0.15                  | 19.81       | 0.67        |
| Tao, 2014        | 4 / 70         | 0.56                        | 0.16                  | 1.89        | 0.35        |
| Toyama, 2014     | 2 / 50         | 1.37                        | 0.24                  | 7.73        | 0.72        |
| Kochhauser, 2014 | 1 / 141        | 0.46                        | 0.09                  | 2.31        | 0.34        |
| Di Biase, 2014   | 1 / 196        | 0.51                        | 0.05                  | 4.95        | 0.56        |
| Dillier, 2014    | 20 / 272       | 0.58                        | 0.33                  | 1.02        | 0.06        |
| Snipelisky, 2014 | 6 / 40         | 1.80                        | 0.55                  | 5.92        | 0.33        |
| Armbruster, 2014 | 8 / 61         | 0.86                        | 0.38                  | 1.96        | 0.72        |
| Cappato, 2015    | 21 / 124       | 1.28                        | 0.64                  | 2.55        | 0.48        |
| Total            |                | 0.84                        | 0.63                  | 1.11        | 0.22        |

For Mendoza, 2014 (0/80 vs. 0/58) POR is not estimable

**Figure 4** Forest plot of minor bleeding events.

**Figure 5** Bleeding risk in studies using uninterrupted rivaroxaban or holding >2 dose of rivaroxaban.

Risk of bleeding during atrial fibrillation ablation

Previous reports indicate an incidence of 2.8% of major bleeding events in patients undergoing AF ablation.\textsuperscript{3} Novel oral anticoagulants have in general been demonstrated to have similar or even lower bleeding rates than VKA\textsuperscript{9–11}. The present meta-analysis
of rivaroxaban studies shows similarly low bleeding incidences with this NOAC compared with VKA, in line with the observations from the randomized rivaroxaban study for which all bleeding episodes were centrally adjudicated. It is also in agreement with recent findings using apixaban for peri-procedural anticoagulation in AF ablation.

Unresolved issues in the use of novel oral anticoagulants during atrial fibrillation ablation

All NOACs have significant handling advantages over VKA in general and in the setting of AF ablation. Current expert consensus documents recommend temporary interruption of NOAC therapy prior to elective procedures including AF ablation. The studies analysed here were not uniformly designed in this respect; whereas some used continuous rivaroxaban administration, others stopped NOAC administration for one or more doses, as in a recent publication on this topic.

Limitations

This meta-analysis is subject to all potential limitations of this kind of analysis. We did not have access to individual patient data from all studies reviewed but had to rely on published information. The vast majority of the data stem from retrospective observational studies, and hence potential confounding cannot be excluded. Patient populations enrolled in individual trials were heterogeneous with regard to the use of the anticoagulants (i.e. uninterrupted/in‐interrupted VKA or rivaroxaban therapy, use of LMWH/heparin bridging, the number of hold dose of rivaroxaban). However, our sensitivity analyses of various patient subgroups revealed no significant differences compared with the main results (Supplementary material online, Table S1–3). There were large variations in the follow-up period of patients, and no long-term follow-up data were available in some of the studies. Furthermore, we had no detailed data available to evaluate if major bleeds on rivaroxaban were associated with more requirements for blood products than those occurring on VKA. These limitations emphasize the need for further randomized trials.

Conclusion

According to this comprehensive meta-analysis, rivaroxaban appears to be a safe alternative to warfarin with no apparent difference or no signal of a difference in efficacy.

Supplementary material

Supplementary material is available at Europace online.

Acknowledgements

The authors would like to acknowledge Sofia Konisti, who provided editorial support with funding from Bayer HealthCare Pharmaceuticals and Janssen Scientific Affairs, LLC.

Funding

Funding to pay the Open Access publication charges for this article was provided by Bayer Healthcare and Janssen Pharmaceuticals.

Conflict of interest: M.V. reports receiving lecture fee from Pfizer and non-financial support from Boston Scientific, outside the submitted work. R.C. reports receiving consulting and lecture fees from Biosense Webster, St. Jude Medical, and Bard. F.E.M. reports receiving consulting and lecture fees from Biosense Webster, Medtronic, St. Jude Medical, and CardioInsight. A.N. reports receiving consulting and lecture fees from Biosense Webster, Boston Scientific, Janssen, St. Jude Medical, Medtronic and Biotronik. S.H.H. reports consulting fees from Bayer Healthcare, during the conduct of the study, and consulting fees from BI, BMS, Gilead, &J, Medtronic, Pfizer, SJM, sanofi aventis, and Cardiome, outside the submitted work.

References

1. Camm AJ, Lip GY, De Caterina R, Savelieva I, Atar D, Hohnloser SH et al. ESC Committee for Practice Guidelines-C.PG. Document Reviewers. 2012 Focused update of the ESC Guidelines for the management of atrial fibrillation: an update of the 2010 ESC Guidelines for the management of atrial fibrillation—developed with the special contribution of the European Heart Rhythm Association. Euro apprentice 2012;14:385–413.
2. Calkins H, Kuck KH, Cappato R, Brugada J, Camm AJ, Chen SA et al. 2012 HRS/EHRA/ECAS Expert Consensus Statement on Catheter and Surgical Ablation of Atrial Fibrillation: recommendations for patient selection, procedural techniques, patient management and follow-up, definitions, endpoints, and research trial design. Euro apprentice 2012;14:528–606.
3. Cappato R, Calkins H, Chen SA, Davies W, Lesaka Y, Kalman J et al. Updated world-wide survey on the methods, efficacy, and safety of catheter ablation for human atrial fibrillation. J Arrhythm Electrophysiol 2010;3:32–8.
4. Santangeli P, Di Biase L, Horton R, Burkhardt JD, Sanchez J, Al-Ahmad A et al. Ablation of atrial fibrillation under therapeutic warfarin reduces periprocedural complications: evidence from a meta-analysis. Circ Arrhythm Electrophysiol 2012;5:302–11.
5. Di Biase L, Burkhardt JD, Santangeli P, Mahanty P, Sanchez J, Horton R et al. Peri-procedural stroke and bleeding complications in patients undergoing catheter ablation of atrial fibrillation with different anticoagulation management: results from the Role of Coumadin in Preventing Thromboembolism in Atrial Fibrillation (AF) Patients Undergoing Catheter Ablation (COMPARE) randomized trial. Circulation 2014;129:2638–44.
6. Ansell J, Hirsh J, Hylek E, Jacobson A, Crowther M, Palatini G. Pharmacology and management of the vitamin K antagonists. American College of Chest Physicians Evidence-Based Clinical Practice Guidelines (8th edition). Chest 2008;133(6 Suppl.):1605–985.
7. Hylek E, Singer D. Risk factors for intracranial hemorrhage in outpatients taking warfarin. Ann Intern Med 1994;120:897–902.
8. Oden A, Fahlen M, Hart RG. Optimal INR for prevention of stroke and death in atrial fibrillation: a critical appraisal. Thromb Res 2006;117:493–9.
9. Connolly SJ, Ezekowitz MD, Yusuf S, Eskandar J, Oldgren J, Parekh A et al. Dabigatran versus warfarin in patients with atrial fibrillation. N Engl J Med 2009;361:1139–51.
10. Patel MR, Mahaffey KW, Garg J, Pan G, Singer DE, Hacke W et al. Rivaroxaban versus warfarin in nonvalvular atrial fibrillation. N Engl J Med 2011;365:883–91.
11. Granger CB, Alexander JH, McMurray JJ, Lopes RD, Hylek EM, Hanna M et al. Apixaban versus warfarin in patients with atrial fibrillation. N Engl J Med 2011;365:981–92.
12. Bernard M, Brabham W, Netzler P, Rowley C, Gold M, Leman M et al. Comparison of atrial fibrillation ablation bleeding and thrombotic complications with dabigatran, rivaroxaban and warfarin. J Am Coll Cardiol 2013;61(10S):E276, “Abstract”.
13. Gaddiyaram VK, Isabel B, Kawata H, Patel J, Megarry T, Josh R et al. Rivaroxaban has similar safety and efficacy as warfarin for peri-procedural anticoagulation for atrial fibrillation ablation. Heart Rhythm 2013;10:PO001–165. “Abstract.”
14. Lahkireddy D, Reddy YM, Di Biase L, Vallakati A, Mansour MC, Santangeli P et al. Feasibility and safety of uninterrupted rivaroxaban for peri-procedural anticoagulation in patients undergoing radiofrequency ablation for atrial fibrillation: results from a multicenter prospective registry. J Am Coll Cardiol 2014;63:982–8.
15. Providencia R, Marijon E, Almenberg JP, Combos S, Combos N, Jourda F et al. Rivaroxaban and dabigatran in patients undergoing catheter ablation of atrial fibrillation. Euro apprentice 2014;16:1137–44.
16. Stepanyan G, Badhwar N, Lee RJ, Marcus GM, Lee BK, Tseng ZH et al. Safety of new oral anticoagulants for patients undergoing atrial fibrillation ablation. J Interv Card Electrophysiol 2014;40:33–8.

17. Murakawa Y, Nogami A, Shoda M, Inoue K, Naito S, Kumagai K et al. Nationwide survey of catheter ablation for atrial fibrillation: the Japanese Catheter Ablation Registry of Atrial Fibrillation (j-CARAF)—report of 1-year follow-up. Circ J 2014; 78:1091–6.

18. Mendoza I, Reina J, Baez-Escudero J, Helguera ME, Pinski SL. Atrial fibrillation radiofrequency ablation on uninterrupted anticoagulation with rivaroxaban versus warfarin. J Cardiovasc Electrophysiol 2014;25:560. “Abstract”.

19. Tao S, Kenchou O, Yuchi O, Yasuhiro S, Kensiuke I, Takeshi S et al. Efficacy and safety of rivaroxaban versus warfarin as uninterrupted anticoagulation for radiofrequency catheter ablation of atrial fibrillation. Heart Rhythm 2014;11:5228. “Abstract”.

20. Toyama H, Kumagai K. Relationship between oral anticoagulants and dose of heparin during procedure in patients undergoing catheter ablation of atrial fibrillation. Heart Rhythm 2014;11:5310–1. “Abstract”.

21. Winkle RA, Mead RH, Engel G, Kong MH, Patrawala RA. Periprocedural interrupted oral anticoagulation for atrial fibrillation ablation: comparison of aspirin, warfarin, dabigatran, and rivaroxaban. Europace 2014;16:1493–9.

22. Kochhäuser S, Khaykin Y, Beardsall J, Juta R, Hache P, Trougou K et al. Comparison of outcomes after cardioversion or atrial fibrillation ablation in patients with differing periprocedural anticoagulation regimens. Can J Cardiol 2014;30:1541–6.

23. Di Biase L, Trivedi C, Mohanty P, Mohanty S, Bai R, Santageli P et al. Feasibility and safety of uninterrupted rivaroxaban in patients undergoing radiofrequency ablation for long standing persistent atrial fibrillation. Circulation 2014;130:A16402. “Abstract”.

24. Diller R, Ammar S, Hessling G, Kaes B, Pavao H, Buatti A et al. Safety of continu-ous periprocedural rivaroxaban for patients undergoing left atrial catheter ablation procedures. Circ Arrhythm Electrophysiol 2014;7:576–82.

25. Snipelisky D, Ray JC, Ung R, Duart M, Kauffman C, Kusumoto F. A comparison of bleeding complications between warfarin, dabigatran, and rivaroxaban in patients undergoing cryoballoon ablation. J Interv Card Electrophysiol 2014;41:231–6.

26. Armbruster HL, Lindsey JP, Moranville HP, Habibi M, Khurram IM, Spragg DD et al. Safety of novel oral anticoagulants compared with uninterrupted warfarin for catheter ablation of atrial fibrillation. Ann Pharmacother 2015;49:278–84.

27. Cappato R, Marchinski F, Hohloiser SH, Naccarelli G, Xiang J, Wilber D et al. Uninterrupted rivaroxaban vs. uninterrupted vitamin K antagonists for catheter ablation in non-valvular atrial fibrillation. European Heart J 2015;36:1805–11.

28. Liberati A, Altman DG, Tetzlaff J, Mulrow C, Gøtzsche PC, Ioannidis JP et al. The PRISMA statement for reporting systematic reviews and meta-analyses of studies that evaluate healthcare interventions: explanation and elaboration. BMJ 2009;339:b2700.

29. da Costa BR, Jüni P. Systematic reviews and meta-analyses of randomized trials: principles and pitfalls. European Heart J 2014;35:3336–45.

30. Schulman S, Angerš U, Bergqvist D, Eriksbønn B, Lassen MR, Fisher W. Subcommittee on Control of Anticoagulation of the Scientific and Standardization Committee of the International Society on Thrombosis and Haemostasis. Definition of major bleeding in clinical investigations of antithrombotic medicinal products in surgical patients. J Thromb Haemost 2010;8:202–4.

31. Slim K, Nini E, Forestier D, Kwiatkowski F, Panis Y, Chippin J. Methodological index for non-randomized studies (minors): development and validation of a new instrument. ANZ J Surg 2003;73:712–6.

32. Borenstein M, Hedges LV, Higgins JP, Rothstein H. A basic introduction to fixed and random effects models for meta-analysis. Res Synth Methods 2010;1:97–111.

33. Bradburn MJ, Deeks JJ, Berlin JA, Russell Locascio A. Much ado about nothing: a comparison of the performance of meta-analytical methods with rare events. Stat Med 2007;26:53–77.

34. Higgins JP, Thompson SG, Deeks JJ, Altman DG. Measuring inconsistency in meta-analyses. BMJ 2003;327:557–60.

35. Borenstein M, Hedges LV, Higgins JPT, Rothstein HR. Introduction to Meta-Analysis. 1st edn. Pondicherry, India: John Wiley & Sons, Ltd., 2009.

36. Begg CB, Mazumdar M. Operating characteristics of a rank correlation test for publication bias. Biometrics 1994;50:1088–101.

37. Gasta F, Caponi D, Platini E, Scaglione M, Toso E, Cesarani F et al. Radiofrequency catheter ablation of atrial fibrillation: a cause of silent thromboembolism? Magnetic resonance imaging assessment of cerebral thromboembolism in patients undergoing ablation of atrial fibrillation. Circulation 2010;122:1667–73.

38. Anselmino M, Matta M, Toso E, Ferraris F, Castagno D, Scaglione M et al. Silent cerebral embolism during atrial fibrillation ablation: pathophysiology, prevention and management. J Air Electrophysiol 2013;15:75–81.

39. Weitz JI, Hesley JS, Sianes KC, Verma A. Periprocedural management of new oral anticoagulants in patients undergoing atrial fibrillation ablation. Circulation 2014;129:1688–94.

40. Sticherling C, Marin F, Binnie D, Boriani G, Calcina H, Dan GA et al. Antithrombotic management in patients undergoing electrophysiological procedures: a European Heart Rhythm Association (EHRA) position document endorsed by the ESC Working Group Thrombosis, Heart Rhythm Society (HRS), and Asia Pacific Heart Rhythm Society (APHRS). Europace 2015;17:1197–214.

41. Hohloiser SH, Camm AJ. Safety and efficacy of dabigatran etexilate during catheter ablation of atrial fibrillation: a meta-analysis of the literature. Europace 2013;15:1407–11.

42. Ayal RLR, Ukaigwe A, Pandit A, Karmacharya P, Pradhan R, Mainali NR et al. Meta-analysis of efficacy and safety of rivaroxaban compared with warfarin or dabigatran in patients undergoing catheter ablation for atrial fibrillation. Am J Cardiol 2014;114:577–82.

43. Phan K, Wang N, Pison L, Kumar N, Hitos K, Thomas SP. Rivaroxaban versus warfarin or dabigatran in patients undergoing catheter ablation for atrial fibrillation: a meta-analysis. Int J Cardiol 2015;185:209–13.

44. Nairroz R, Sardar P, Pina M, Aronow WS, Sewani A, Mukherjee D et al. Meta-analysis of risk of stroke and thrombo-embolism with rivaroxaban versus vitamin K antagonists in ablation and cardioversion of atrial fibrillation. Int J Cardiol 2015;187:345–53.

45. Li W, Gao C, Li M, Wang X, Qi D, Zhang Y et al. Safety and efficacy of rivaroxaban versus warfarin in patients undergoing catheter ablation of atrial fibrillation: a meta-analysis of observational studies. Diss Med 2015;19:193–201.

46. Di Biase L, Lakkireddy D, Trivedi C, Deneke T, Martinsek M, Mahaney S et al. Feasibility and safety of uninterrupted periprocedural apixaban administration in patients undergoing radiofrequency catheter ablation for atrial fibrillation: results from a multicenter study. Heart Rhythm 2015;12:1162–8.

47. Heidbuchel H, Verhamme P, Alings M, Antz M, Hacke W, Oldgren J et al. European Heart Rhythm Association. European Heart Rhythm Association Practical Guide on the use of new oral anticoagulants in patients with non-valvular atrial fibrillation. Europace 2015;17:625–51.

48. Rillig A, Lin T, Pesman J, Heeger CH, Lemes C, Metzner A et al. Apixaban, rivarox- aban and dabigatran in patients undergoing atrial fibrillation ablation. J Cardiovasc Electrophysiol 2015 Oct 14. doi:10.1111/jce.12856. [Epub ahead of print].